IP Library › Granted Patent US 12,653,812
Granted Patent B2
US 12,653,812 · App. 18/510,165 · Granted Jun 16, 2026

Animal treatments

Inventors: David Rock (California, MO); Mark Ridall (Skillman, NJ)
Assignee: NewMarket Pharmaceuticals LLC
A61K31/4439A61K9/0053A61K31/135A61K31/137A61K31/155A61K31/341A61K31/403A61K31/4164A61K31/4174A61K31/44A61K31/5415A61K31/635A61K31/7048C07D307/52C07D401/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,812
App. No.
18/510,165
Granted
Jun 16, 2026
Kind
B2
Abstract

Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of an immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.

Claims (22)

1 . A method of treating a condition in an animal in need thereof, the method comprising:

determining a dose of detomidine required; and

administering orally to a pre-gastric mucosal cell of the animal a Direct Systemic Introduction (DSI) composition comprising the dose of detomidine;

wherein the DSI composition in the animal's oral cavity is dissolved in less than about 75 seconds; and

wherein the required dose of detomidine is determined by greater than 50% of the administered detomidine being detected in the animal's circulatory system via the pre-gastric mucosal cells lining the animal's alimentary canal prior to the animal's secretory stomach.

2 . The method of claim 1 , wherein the DSI composition is dissolved in less than about 30 seconds.

3 . The method of claim 1 , wherein the DSI composition provides an immediate release of detomidine.

4 . The method of claim 1 , wherein the animal is one of a human, an equine, a bovine, a canine, a feline, an ovine, a caprine, and a porcine.

5 . The method of claim 1 , wherein detomidine is present in the DSI composition in an amount ranging from about 0.5% to about 50% by weight of the overall composition.

6 . The method of claim 1 , wherein the DSI composition further comprises one or more distinct agents of an excipient, a sweetening agent, and/or a flavoring agent.

7 . The method of claim 6 , wherein the excipient includes one or more distinct agents of gelatin, mannitol, and/or another sugar alcohol.

8 . The method of claim 6 , wherein the sweetening agent includes aspartame.

9 . The method of claim 6 , wherein the flavoring agent includes one or more distinct agents of a mint flavoring agent, a peppermint flavoring agent, a fruit flavoring agent, a meat flavoring agent, and/or a fish flavoring agent.

10 . A freeze-dried Direct Systemic Introduction (DSI) composition comprising:

an effective dose of detomidine adapted to exert a therapeutic effect on an animal when administered orally and absorbed via pre-gastric mucosa of the animal to obtain greater than 50% of the administered detomidine being detected in the animal's circulatory system, wherein the detomidine is present in the DSI composition in an amount ranging from about 0.5% to about 50% by weight of the overall composition; and

wherein the DSI composition has an oral dissolution time of less than about 30 seconds.

11 . The freeze-dried DSI composition of claim 10 , further comprising one or more distinct agents as an excipient, a sweetening agent, and/or a flavoring agent.

12 . The freeze-dried DSI composition of claim 11 , wherein the excipient includes one or more distinct agents of gelatin, mannitol, and/or another sugar alcohol.

13 . The freeze-dried DSI composition of claim 11 , wherein the sweetening agent includes aspartame.

14 . The freeze-dried DSI composition of claim 11 , wherein the flavoring agent includes one or more distinct agents of a mint flavoring agent, a peppermint flavoring agent, a fruit flavoring agent, a meat flavoring agent, and/or a fish flavoring agent.

15 . The freeze-dried DSI composition of claim 10 , wherein the DSI composition provides an immediate release of the effective dose of detomidine that is absorbed via pre-gastric mucosa when administered orally.

16 . The freeze-dried DSI composition of claim 10 , wherein the effective dose of the detomidine is determined by greater than 50% of the administered detomidine is detectable within the animal's circulatory system through absorption via the pre-gastric mucosa.

Continuity (7)
Continuation 17453566 · Nov 4, 2021
Continuation 16886093 · May 28, 2020
Continuation 16014290 · Jun 21, 2018
Continuation 14275019 · May 12, 2014
Continuation 13343692 · Jan 4, 2012
Provisional Application 61437763 · Jan 31, 2011
Related Publication 20240091211A1 · Mar 21, 2024
References Cited (59)
US 6193999B1 · Gennadios · 2001 [cited by applicant]
US 6471992B1 · Yoo et al. · 2002 [cited by applicant]
US 6596311B1 · Dobetti · 2003 [cited by applicant]
US 6709669B1 · Murray et al. · 2004 [cited by applicant]
US 7122198B1 · Singh et al. · 2006 [cited by applicant]
US 7939561B2 · Schellenger et al. · 2011 [cited by applicant]
US 8545879B2 · Burns et al. · 2013 [cited by applicant]
US 8647668B2 · Tanaka et al. · 2014 [cited by applicant]
US 8722636B2 · Rock et al. · 2014 [cited by applicant]
US 9402835B2 · Rock et al. · 2016 [cited by applicant]
US 10022361B2 · Rock et al. · 2018 [cited by applicant]
US 10064849B2 · Ridall et al. · 2018 [cited by applicant]
US 10695332B2 · Ridall et al. · 2020 [cited by applicant]
US 10702509B2 · Rock et al. · 2020 [cited by applicant]
US 10918631B2 · Ridall et al. · 2021 [cited by applicant]
US 20020035076A1 · Parks · 2002 [cited by applicant]
US 20030031711A1 · Fara et al. · 2003 [cited by applicant]
US 20040248942A1 · Hepburn et al. · 2004 [cited by applicant]
US 20070042023A1 · Puri et al. · 2007 [cited by applicant]
US 20070184106A1 · Schellenger et al. · 2007 [cited by applicant]
US 20070275058A1 · Tanaka et al. · 2007 [cited by applicant]
US 20080096971A1 · Baxter et al. · 2008 [cited by applicant]
US 20110256229A1 · Nystrom et al. · 2011 [cited by applicant]
US 20120196819A1 · Rock et al. · 2012 [cited by applicant]
US 20120219628A1 · Lim et al. · 2012 [cited by applicant]
US 20150018293A1 · Rock et al. · 2015 [cited by applicant]
US 20150018391A1 · Rock et al. · 2015 [cited by applicant]
US 20150133504A1 · Ridall et al. · 2015 [cited by applicant]
US 20160038473A9 · Rock et al. · 2016 [cited by applicant]
US 20160095825A9 · Rock et al. · 2016 [cited by applicant]
US 20180360816A1 · Rock et al. · 2018 [cited by applicant]
US 20180369221A1 · Ridall et al. · 2018 [cited by applicant]
US 20200276173A1 · Ridall et al. · 2020 [cited by applicant]
US 20200289487A1 · Rock et al. · 2020 [cited by applicant]
US 20210128542A1 · Ridall et al. · 2021 [cited by applicant]
CA 2369951 · 2000 [cited by applicant]
EP 1891937 · 2008 [cited by applicant]
WO 0050038 · 2000 [cited by applicant]
WO 02058735 · 2002 [cited by applicant]
WO 2004067004 · 2004 [cited by applicant]
WO 2006048501 · 2006 [cited by applicant]
WO 2007002125 · 2007 [cited by applicant]
WO 2012106058 · 2012 [cited by applicant]
WO 2013165468 · 2013 [cited by applicant]
Kaukinen et al. Bioavailability of detomidine administered sublingually to horses as an oromucosal gel. J. vet. Pharmacol. Therap. 34, 76-81, 2010 (First published: Jan. 10, 2011) (Year: 2011). [cited by examiner]
Hahm et al. Orally Disintegrating Tablets and Related Tablet Formulations. Augsburger, L.L., & Hoag, S.W. (Eds.). (2008). Pharmaceutical Dosage Forms—Tablets: Rational Design and Formulation (3rd ed.). CRC Press. https:… [cited by examiner]
Arvanitoyannis et al, “Edible films made from hydroxypropyl starch and gelatin and plasticized by polyols and water,” Carbohydrate Polymers 36: 105-119 (1998). [cited by applicant]
Chubineh et al.: “Proton Pump Inhibitors: The Good, the Bad, and the Unwanted,” Southern Medical Journal, vol. 105, No. 11, pp. 613-618, Nov. 2012. [cited by applicant]
Extended European Search Report in EP 12875765.5 (corresponds to PCT/US2012/070031) dated Aug. 31, 2015, 9 pages. [cited by applicant]
Glossary of Medical Education Terms, Institute of International Medical Education. http://www.iime.org/glossary.htm, accessed on Jan. 2013, 43 pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2012/020242 dated Aug. 6, 2013, 6 pages. [cited by applicant]
International Search Report for International Application No. PCT/US2012/020242 dated Aug. 30, 2012, 5 pages. [cited by applicant]
International Search Report for International Application No. PCT/US2012/070031 dated Feb. 26, 2013, 3 pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2012/070031 dated Nov. 4, 2014, 6 pages. [cited by applicant]
Liles et al. “The use of non-steroidal anti-inflammatory drugs for the relief of pain in laboratory rodents and rabbits.” Laboratory Animals 26:241-255, 1992, 15 pages. [cited by applicant]
Mona Nagar et al.: “Formulation, Evaluation and Comparison of Fast-Dissolving Tablet of Nimesulide by Using Crospovidone as Superdisintegrant,” International Journal of Pharmaceutical Sciences and Drug Research, 2009, 1… [cited by applicant]
R. Panigrahi et al.: “A Review on Fast Dissolving Tablets,” WebMedCentral Pharmaceutical Sciences, Sep. 29, 2010, 1(9), pp. 1-15. [cited by applicant]
www.avma.org/issues/drugs/compounding/veterinary_compounding_brochure.asp, Veterinary Compounding Brochure, American Veterinary Medical Association (AVMA) Jun. 2001, 6 pages. [cited by applicant]
www.fda.gov/AnimalVeterinary/NewsEvents/FDAVeterinarianNewsletter/ucm10026-8.htm, Mar./Apr. 2003, 4 pages. [cited by applicant]